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A plasminogen activator inhibitor was purified from human comified cell extract by DEAE-Sepharose, 
Sephacryl S-200, and high-performance liquid chromatographies on hydroxyapatite HPHT and anion-ex- 
changer Mono Q at pH 7.2 and 8.0. The purified inhibitor showed iW, 43000 and pZ 5.2. 50% inhibition 
of fibrinolytic activity (1.5 IU) of urokinase and tissue-type plasminogen activator wasattained by 0.60 ng 
and 11 .O ng purified inhibitor, respectively. Synthetic substrate assay demonstrated slow tight-binding inhi- 
bition to both urokinase and tissue-type plasminogen activator. The inhibitor did not inactivate plasmin, 
thrombin, glandular kallikrein or trypsin. 
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1. INTRODUCTION 
Plasminogen activator (PA) which converts 
fibrinolytic proenzyme, plasminogen, to plasmin 
has been demonstrated with epidermal disorders, 
such as psoriasis [I,21 and bullous diseases [3]. In 
normally keratinized cells, however, PA activity 
was not detectable as reported by Haustein [l] and 
Ryan and co-workers [4]. In our screening test for 
serine proteinase inhibitors [5], we demonstrated a
possible regulating factor for PA in human cor- 
nified cell extract. The present study reports 
purification of the epidermal PA inhibitor. 
2. MATERIALS AND METHODS 
2.1. Enzymes and substrates 
Purified high molecular mass urokinase (55 
kDa) was kindly given by Kowa, Tokyo. Tissue- 
type plasminogen activator (t-PA) from human 
melanoma cells (>90% two chain) (Bioscot 
Limited, Edinburgh), plasmin and thrombin 
(Green Cross, Osaka), trypsin (type III) and glan- 
dular kallikrein (Sigma, St. Louis) were purchased. 
PyroGlu-Gly-Arg-p-nitroanilide (pNA) (S-2444), 
Ile-Pro-Arg-pNA (S-2288), Phe-pipecolyl-Arg- 
pNA (S-2238), Val-Leu-Lys-pNA (S-225 l), and 
Tissue-type plasminogen activator Binding inhibition 
Val-Leu-Arg-pNA (S-2266) were the products of 
Kabi Diagnostica, Stockholm. Benzoyl-Arg-pNA 
(BApNA) was from Peptide Institute, Osaka. 
2.2. Extraction and purification of epidermal PA 
inhibitor 
Human cornified cells (30 g) scraped from heels 
of 30 healthy individuals (age 23-35) were ex- 
tracted in 100 mM Tris-HCl (pH 8.0) containing 
140 mM NaCl for 2 h at 4°C. Supernatant was 
concentrated with Amicon using YM 10 membrane 
and applied to a DEAE-Sepharose column 
equilibrated with 20 mM phosphate buffer (pH 
7.5). Inhibitor fraction eluted with increasing NaCl 
concentration up to 0.6 M was fractionated by 
Sephacryl S-200 gel chromatography equilibrated 
with 20 mM phosphate buffer + 0.14 M NaCl. 
The inhibitor fraction was then applied on hydrox- 
yapatite HPHT column (Bio-Rad) equilibrated 
10 mM phosphate buffer (pH 6.8) + 0.3 M CaClz 
and eluted with increasing phosphate concentra- 
tion up to 0.4 M. This was followed by high- 
performance anion-exchange chromatography on 
Mono Q (Pharmacia) twice. Firstly, Mono Q col- 
umn was equilibrated with 20 mM phosphate buf- 
fer (pH 7.2) and eluted with increasing NaCl 
concentration up to 0.9 M. Secondly, the obtained 
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inhibitor fraction was applied on Mono Q column 
equilibrated with 20 mM Tris-HCl (pH 8.0). 
SDS-polyacrylamide gel eiectrophoresis was car- 
ried out by the method of Laemmli [6]. 
In order to detect the inhibitor activity of the 
separated protein band, reverse fibrin autography 
[7] was performed after SDS-polyacrylamide gel 
electrophoresis with modifications. Urokinase 
(final concentration, 0.13 IU/ml) was incor- 
porated into the fibrin-agarose indicator gels in the 
presence of the purified dog plasminogen (final 
concentration, 15 yg/ml). The gels were incubated 
at 37°C for 3 h. 
Protein concentration was determined by the 
method of Lowry et al. [8] using bovine serum 
albumin as standard. 
Isoelectric point of the inhibitor was studied by 
chromatofocusing on Mono P (Pharmacia) using 
an inhibitor fraction obtained from first Mono Q 
chromatography. Elution was done with polybuf- 
fer with pH interval 7 and 4. 
2.3. Calorimetric inhibitor assay 
Substrates used were S-2444 for urokinase; 
S-2288, t-PA; S-2251, plasmin; S-2238, thrombin; 
S-2266, glandular kallikrein; and BApNA, trypsin. 
Enzyme concentration was standardized to liberate 
1.4 nmol p-nitroaniline per min in each enzyme- 
substrate combination in the following assay 
system. Inhibitor sample (0.01-0.05 ml) or buffer 
(control) was preincubated with 0.1 ml enzyme in 
0.80-0.84 ml Tris-HCl (pH 8.5) (totally, 0.95 ml) 
at 25°C for 30 min (60 min for t-PA) or specified 
intervals. Reaction was started by the addition of 
0.05 ml of 4 mM substrate at 37°C and absor- 
bance at 405 nm was monitored. In this condition, 
molar concentration of enzymes determined by ac- 
tive site titration method with p-nitrophenyl 
p’-guanidinobenzoate (Sigma) [9] was 2.09 nM for 
urokinase; 3.86 nM, t-PA; 0.14 nM, plasmin; 
0.03 nM, thrombin; and 2.4 nM, trypsin. Molar 
concentrations of glandular kallikrein were not 
determined. Inhibitor activity was expressed by the 
enzyme activity (nmol/min = unit) that was in- 
hibited. 
2.4. Fibrin plate assay 
Mixtures containing 10 ,ul enzyme (1.5 IU/ml) 
and 10~1 inhibitor sample or buffer were placed 
on plasminogen-rich fibrin plates [lo] and in- 
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cubated for 18 h at 37°C. Squared diameter of 
lysis zone was plotted versus concentrations (IU) 
of urokinase or t-PA for standard curves. In- 
hibitor activity (percent inhibition) was calculated 
from the standard curve. 
3. RESULTS 
3.1. Purification of epidermal PA inhibitor 
DEAE-Sepharose chromatography of Tris- 
buffered saline extract of human cornified cells 
demonstrated a peak of urokinase inhibitor activi- 
ty which was eluted at approx. 0.15 M NaCl. The 
Sephacryl S-200 gel chromatography showed the 
inhibitor activity for urokinase at approx. h4, 
40000. In the following hydroxyapatite HPHT col- 
umn, inhibitor activity was detected at the frac- 
tions eluted with 0.35-0.40 M phosphate. In the 
first Mono Q chromatography at pH 7.2 inhibition 
for urokinase was detected in the fraction eluted at 
approx. 0.12 M NaCl. The second Mono Q 
chromatography at pH 8.0 demonstrated only one 
protein peak in which inhibitor activity coincided 
(fig. 1). SDS-polyacrylamide gel electrophoresis of 
the final preparation showed a single protein band 
with an Mr of 43000 (fig.2). Reverse fibrin 
autography demonstrated that the isolated protein 
with IV?, 43000 possesses the inhibitor activity 
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Fig. 1. The second Mono Q chromatography at pH 8.0. 
Solid line shows absorbance at 280 nm. Inhibition for 
urokinase (o---o) was measured by calorimetric assay 
using S-2444 as substrate. 
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Fig.2. Analysis of the purified inhibitor. Approx. 7,ug 
of the inhibitor from the second Mono Q 
chromatography was applied on SDS-polyacrylamide 
slab gels. After electrophoresis, the gel was stained with 
Coomassie brilliant blue (lane A, molecular mass 
markers and B, inhibitor fraction), or analyzed for 
inhibitor activity by reverse fibrin autography (lane C). 
Molecular mass of the inhibitor was estimated to be 
43 kDa. 
toward urokinase (fig.2). Isoelectric point of the 
PA inhibitor was estimated to be 5.2 by 
chromatofocusing on Mono P (not shown). 3.2. Inhibitor activity 
Table 1 summarizes the purification steps of Purified inhibitor inactivated both urokinase 
epidermal PA inhibitor. Specific activity increased and t-PA in a dose-dependent manner in fibrin 
1745fold with a yield of 5.1%. plate assays (fig.3A). It was calculated that 0.60 ng 
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Fig.3. Inhibitor activity of the purified epidermal PA 
inhibitor on serine proteinases. Residual enzyme activity 
((70) was plotted versus various amounts of purified 
inhibitor. (A) Fibrin plate assay for urokinase (M) 
and t-PA (O---O). (B) Calorimetric assay for urokinase 
(o----o), t-PA (O---O), plasmin (L--A), thrombin 
(M), glandular kallikrein (ti), and trypsin 
(e--*). 
Table 1 
Summary of purification 
Step 
Crude extract 
DEAE-Sepharose 
Sephacryl S-200 
HPHT 
Mono Q at pH 7.2 
Mono Q at pH 8.0 
Volume 
(ml) 
Protein 
(mg) 
Total Specific 
activity activity 
(unit) (unit/mg) 
513 1508.0 17.3 0.011 100 1 
46.5 46.2 16.8 0.364 97 33 
15.8 16.6 12.3 0.741 71 67 
6.8 1.36 2.43 1.79 14 163 
3.5 0.234 1.09 4.65 6.3 423 
2.5 0.046 0.89 19.2 5.1 1745 
Yield Purification 
(%) factor 
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of the inhibitor inactivated 50% activity of 1.5 IU 
of urokinase, whereas 11.0 ng was needed for 
1.5 IU of t-PA, showing 18-times less potency in 
inhibiting t-PA in fibrinolysis. Fig.3B shows the 
effect of the purified inhibitor in the calorimetric 
inhibitor assay. The purified inhibitor (50 ng) inac- 
tivated 50% of 115 ng of urokinase. In molar con- 
centration, 1.2 nM of the inhibitor showed 50070 
inhibition for 2.09 nM urokinase, revealing 1: 1 
stoichiometric interaction between the inhibitor 
and urokinase. However, 1.65 pg (39.6 nM) of the 
inhibitor was required for 50% inhibition for 
3.86 nM t-PA, showing that 20-times as much in- 
hibitor is needed to inactivate t-PA on a molar 
basis. The purified inhibitor did not show any in- 
hibitory effect on plasmin, thrombin, glandular 
kallikrein or trypsin. 
3.3. Time course of inhibition 
The time course of inhibition by the epidermal 
PA inhibitor demonstrated a slow, tight-binding 
characteristic toward urokinase reaching the max- 
imum inhibition level at 30 min (fig.4). Similar 
time dependency was observed for t-PA, although 
it required 60 min for the maximum inhibition. 
100%’ 
90 - 
b 
.z 
80 -? 
I 
J 70' 
s 
t 
60 - 
2 
: 
50 - 
.+ 
3 
40 - 
.z 30 
: 
'. 
a 
20 - 
'*o-__i, 
10 - 
0', , , ,I 
10 20 30 40 50 60mi, 
Time 
Fig.4. Time course of inhibition. Urokinase (2.09 nM) 
and t-PA (3.86 nM) were preincubated with 0.06 pg and 
1.8 /~g of the purified inhibitor, respectively. After 
appropriate intervals of preincubation at 25°C S-2444 
(urokinase assay) (M) or S-2288 (t-PA assay) 
(O---O) were added and residual enzyme activity (COO) 
was plotted. 
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4. DISCUSSION 
The epidermal PA inhibitor is a slow-acting in- 
hibitor with an apparent M, 0: 43000 and a pZ of 
5.2. A slow-acting PA inhibitor was also purified 
from rat mammary adenocarcinoma cells [ 111. It 
showed less potent inhibition on t-PA than 
urokinase, as well, although its size (Mr 66000) and 
pZ (4.5) were different from the epidermal PA in- 
hibitor. In addition, the epidermal inhibitor was 
distinct from fast-acting PA inhibitors recently 
purified from other tissues. Partially purified 
placenta inhibitor (Mr 48000) instantaneously inac- 
tivated human ovarian carcinoma PA and 
urokinase [ 121. The leucocyte urokinase inhibitor 
(Mr 68000, pZ 4.4-4.5) also showed immediate in- 
activation of urokinase [ 131. Unusually stable PA 
inhibitor (Mr 55 000, pZ 4.5-5.0) from cultured en- 
dothelial cells rapidly inactivated vascular PA and 
urokinase [14]. The epidermal PA inhibitor was 
clearly different from protease nexin (Mr 5 1000 
and pZ 7.5-7.8) [ 151 which inactivated not only PA 
but also other serine proteinases, or from minac- 
tivin (Mr 66 000) [161, a specific urokinase inhibitor 
of human monocyte product. In addition, 
crz-plasmin inhibitor [ 171, the major anti- 
fibrinolytic inhibitor in plasma, showed slow in- 
hibition to urokinase, however it possessed strong 
inhibitor activity on plasmin which is not inhibited, 
by the epidermal inhibitor. 
The epidermal inhibitor showed stronger in- 
hibitory effect on urokinase than t-PA in both 
fibrinolytic and peptide hydrolytic assays. 
However, no inhibitory effect was observed for 
other serine proteinases. From table 1, the content 
of the epidermal PA inhibitor in the starting ex- 
tract was calculated as approx. 0.9 mg/1500 mg of 
extractable protein. This concentration is lower 
than that of the cysteine proteinase inhibitor 
(31.6 mg/1500 mg; unpublished) contained in the 
same starting extract. Although epidermal cells 
immuno-histochemically showed urokinase an- 
tigen in granular layer of normal epidermis [ 181, 
activity of urokinase is not detectable in normal 
epidermis [I ,4,5] but appeared to be enhanced in 
psoriatic conditions (Hibino et al., submitted). 
Therefore, the function of epidermal PA inhibitor 
is postulated in normally differentiated epidermal 
cells. 
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